Sylics and partners awarded Horizon 2020 grant

Through collaboration between outstanding European academic and industry groups, the project will improve and apply our knowledge of the comorbid basis and clinical overlap of schizophrenia, autism, and intellectual disability. In addition to the overall coordination of the project, Sylics will contribute its expertise with behavioural phenotyping and in vivo efficacy studies – in particular with testing novel compounds using our automated behavioural screening platform AHCODA.